Sobi vidareutvecklar Gamifant® (emapalumab) vid gammainterferon-driven sepsis (IDS) baserat på topline-data från EMBRACE (2) ...
Sobi (STO: SOBI) today announced that topline results from the Phase 2a EMBRACE study evaluating Gamifant (emapalumab) for interferon-gamma (IFN?)-driven ...
Under normal conditions, cytokines aid in pathogen recognition and elimination while contributing to immune system ...
Gordon Scott has been an active investor and technical analyst or 20+ years. He is a Chartered Market Technician (CMT). Samantha (Sam) Silberstein, CFP®, CSLP®, EA, is an experienced financial ...
Background Hepatocellular carcinoma (HCC) is a leading cause of cancer mortality with limited therapeutic options. Despite ...
Background Prehospital delays remain critical barriers to timely acute coronary syndrome (ACS) care, particularly for ...
News-Medical.Net on MSN
Common blood signals explain why chronic diseases cluster as we age
This population-based study shows that shared and pattern-specific blood biomarkers reflect biological vulnerability ...
PDF files have become ubiquitous in our multi-platform world. This convenient file format makes it possible to view and share documents across various devices using various operating systems and ...
Plus Therapeutics, Inc. (Nasdaq: PSTV) ("Plus" or the "Company"), a healthcare company developing and commercializing precision diagnostics and radiopharmaceuticals ...
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.
In a significant move aimed at strengthening regulatory clarity for cancer related medical technologies, the Central Drugs ...
Through a recent notice, the Undergraduate Medical Education Board (UGMEB) of the National Medical Commission (NMC) has ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback